OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

OrthoPediatrics Corp.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Liquidia Corp (Symbol: LQDA), where a total of 9,946 contracts have traded so far, representing approximately 994,600 underlying shares. That amounts to about 48.6% of LQDA's average daily trading volume over the past month of 2.0 million shares. Particularly high volume was seen for the $15 strike call option expiring August 15, 2025, with 2,219 contracts trading so far today, representing approximately 221,900 underlying shares of LQDA. Below is a chart showing LQDA's trailing twelve month trading history, with the $15 strike highlighted in orange:
Airbnb Inc (Symbol: ABNB) options are showing a volume of 19,792 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 48.6% of ABNB's average daily trading volume over the past month, of 4.1 million shares. Especially high volume was seen for the $140 strike call option expiring July 18, 2025, with 3,799 contracts trading so far today, representing approximately 379,900 underlying shares of ABNB. Below is a chart showing ABNB's trailing twelve month trading history, with the $140 strike highlighted in orange:
And OrthoPediatrics Corp (Symbol: KIDS) saw options trading volume of 618 contracts, representing approximately 61,800 underlying shares or approximately 47.5% of KIDS's average daily trading volume over the past month, of 130,020 shares. Particularly high volume was seen for the $22.50 strike call option expiring August 15, 2025, with 616 contracts trading so far today, representing approximately 61,600 underlying shares of KIDS. Below is a chart showing KIDS's trailing twelve month trading history, with the $22.50 strike highlighted in orange:
For the various different available expirations for LQDA options, ABNB options, or KIDS options, visit StockOptionsChannel.com.
John Paulson Stock Picks
Institutional Holders of IYLD
Funds Holding MNDY
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Friday Option Activity: LQDA, ABNB, KIDS

Hologic HOLX has been gaining from new strategic product launches across Diagnostics and Breast Health. However, macroeconomic issues and unfavorable FX headwinds continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently.
Major Factors Driving HOLX Stock Growth
Among Hologic’s advanced diagnostic products, primary revenue-generating ones are molecular diagnostic assays, which run on advanced instrumentation systems (Panther, Panther Fusion and Tigris), ThinPrep cytology system and the Rapid Fetal Fibronectin Test. With solid 10.5% growth, excluding COVID-19 sales in the fiscal third quarter of 2024, the Molecular Diagnostics business has consistently maintained high-single to double-digit gains in 13 of the last 15 quarters. Growth continues to be driven by the ongoing adoption and utilization of the broad menu in the Panther platform.
In Breast Health, Hologic expanded its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery. The business is thriving primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment, with key profitable offerings such as 3D digital mammography systems, image analytics software utilizing artificial intelligence, ultrasound imaging and minimally invasive breast biopsy guidance systems. In the third quarter of fiscal 2024, revenues increased 7.1% (excluding the divested SSI business), driven by domestic and international growth of 7.2% and 12.1%, respectively.
The company’s international sales have been a major catalyst in the past few years, growing 5.1% year over year in the third quarter of fiscal 2024. Molecular STI testing, cytology and MyoSure experienced strong growth in the global markets. However, the company perceives it as still in the early phase of utilizing its expanded Panther installed base. Similarly, while international cytology and STI testing have more dominant U.S. revenues, they are expected to become meaningful revenue drivers in the international markets with time.
In order to streamline its operations and reduce the cost of revenues, Hologic has adopted a few significant strategies over the past few years. The company has invested deliberately and opportunistically in commercial areas where management has recognized a good return. These include Hologic’s Genius marketing campaign in Breast Health, cervical cancer co-testing initiatives in Diagnostics, along with efforts to gain competitive market share with NovaSure.
Hologic, Inc. Price
Hologic, Inc. price | Hologic, Inc. Quote
Per management, these strategic initiatives are already paying off through increased brand awareness, market share gains, and price stability, all of which will contribute to the company’s higher sales. In the third quarter of fiscal 2024, the company was awarded the Innovative Technology Contract by Vizient, which expands access to its Surgical product lineup. The contract recognized Hologic’s CoolSeal advanced energy portfolio and JustRight 5 mm stapler for their potential to enhance clinical care, patient safety and healthcare worker safety or improve business operations of healthcare organizations.
The stock has gained 12.2% year to date, compared with the industry’s 7.6% rise. With the company currently focusing on the expansion of diagnostics assay and breast health offerings in global markets, we expect the stock to continue its upward movement in the coming days.
Major Downsides for HOLX
Continued concerns about the systemic impact of potential long-term and widespread recession have added to market volatility and diminished expectations for economic growth. The effect of the worldwide political and social uncertainty, including the impact on trade regulations and tariffs, economic disruptions as well as the ongoing supply chain constraints, have reportedly hampered the costs and sales of Hologic’s products in certain countries in recent times. In the third quarter of fiscal 2024, Hologic’s cost of revenues (product, service and other) rose about 1.9% year over year, while selling, general and administration expenses increased 4.2%.
These uncertainties surrounding global economic conditions and financial markets may cause medical equipment purchasers to decrease their medical health insurance premiums and procurement activities. Additionally, higher unemployment rates and health insurance premiums, co-payments and deductibles may result in cost-conscious consumers making fewer trips to their physicians and specialists, affecting the demand for the company’s products and procedures.
We remain worried about the significant challenges Hologic faces owing to unfavorable foreign currency impact that has been adversely impacting the company’s overall performance in the past few quarters. The company’s international sales are often denominated in foreign currencies, including the euro, UK pound and renminbi. Changes in currency exchange rates, particularly the increase in the value of the dollar against any such foreign currencies, may reduce the reported value of Hologic’s revenues outside the United States and associated cash flows. The company expects about $3 million adverse currency impact in the fourth quarter.
For several quarters in a row, declining COVID-19 assay revenues have been a headwind to some of the company’s key performance metrics. Although the company returned to growth in the fiscal third quarter, the potential impact of the COVID-19 sales downturn still lingers.
Hologic’s fiscal 2024 guidance assumes $70 million from COVID-19 assay sales, including $7 million in the fourth quarter of fiscal 2024. Overall, revenues from COVID-19-related items are expected to be approximately $105 million in fiscal 2024.
Key Picks
Some better-ranked stocks in the broader medical space are TransMedics Group TMDX, AxoGen AXGN and OrthoPediatrics KIDS. While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for TransMedics’ 2024 earnings per share have moved up 2.5% to $1.23 in the past 30 days. Shares of the company have soared 156.5% in the past year compared with the industry’s 17.5% growth. TMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year, compared with the industry’s 17.6% growth. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for OrthoPediatrics’ 2024 loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 17.1% against the industry’s 20.8% growth. In the last reported quarter, it delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
AxoGen, Inc. (AXGN) : Free Stock Analysis Report
OrthoPediatrics Corp. (KIDS) : Free Stock Analysis Report
TransMedics Group, Inc. (TMDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

HOLX Stock Gains From New Offerings Despite Macro Issues

In trading on Wednesday, shares of OrthoPediatrics Corp (Symbol: KIDS) crossed above their 200 day moving average of $29.42, changing hands as high as $30.11 per share. OrthoPediatrics Corp shares are currently trading up about 2% on the day. The chart below shows the one year performance of KIDS shares, versus its 200 day moving average:
Looking at the chart above, KIDS's low point in its 52 week range is $23.10 per share, with $45.96 as the 52 week high point — that compares with a last trade of $29.77.
Click here to find out which 9 other stocks recently crossed above their 200 day moving average »
Also see:
CRCT Videos
West Pharmaceutical Services shares outstanding history
XNCR Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

KIDS Crosses Above Key Moving Average Level

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 17.86%. A quarter ago, it was expected that this maker of orthopedic devices would post a loss of $0.20 per share when it actually produced a loss of $0.13, delivering a surprise of 35%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
OrthoPediatrics, which belongs to the Zacks Medical - Instruments industry, posted revenues of $37.61 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 0.06%. This compares to year-ago revenues of $30.99 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
OrthoPediatrics shares have lost about 16.2% since the beginning of the year versus the S&P 500's gain of 6.5%.
What's Next for OrthoPediatrics?
While OrthoPediatrics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for OrthoPediatrics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.38 on $40.61 million in revenues for the coming quarter and -$0.96 on $197.65 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, ClearPoint Neuro, Inc. (CLPT), has yet to report results for the quarter ended December 2023. The results are expected to be released on March 12.
This company is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of -22.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
ClearPoint Neuro, Inc.'s revenues are expected to be $6.4 million, up 23.8% from the year-ago quarter.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

OrthoPediatrics Corp.

Price history and volume

Shares 360

Investment risk — low

Investment potential — medium

Security parameters